OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kamath on the Inclusion of Underrepresented Groups in Clinical Trials

June 24th 2022

Suneel Kamath, MD, discusses the importance of including underrepresented patient populations in clinical trials.

Dr. Tawbi on the Safety of Relatlimab Plus Nivolumab in Melanoma

June 24th 2022

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Dr. Carraway on the Importance of Testing for Biomarkers in Patients with MDS and AML

June 23rd 2022

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Dr. Spira on the CNS Activity of Adagrasib in NSCLC

June 23rd 2022

Alexander I. Spira, MD, PhD, FACP, discusses the activity of adagrasib in patients with non–small cell lung cancer and central nervous system metastases.

Dr. Monk on Platinum Ineligibility and Emerging ADCs in Ovarian Cancer

June 23rd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the role platinum-based chemotherapy in recurrent ovarian cancer, plus emerging antibody-drug conjugates in the space.

Dr. DeAngelo on Rates of CRS with Obe-cel in ALL

June 22nd 2022

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Dr. Krishnan of the Effectiveness of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Dr. Carrizosa on the Efficacy Findings of the CRESTONE Trial in NRG1 Fusion–Positive Solid Tumors

June 20th 2022

Daniel Carrizosa, MD, MS, discusses the efficacy findings of the phase 2 CRESTONE trial in patients with NRG1 fusion–positive, advanced solid tumors.

Dr. Sandhu on the Design of the MAGNITUDE trial in Prostate Cancer

June 20th 2022

Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer

June 20th 2022

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Wenham on the Role of ADCs in Ovarian Cancer

June 20th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the role of antibody-drug conjugates in ovarian cancer.

Dr. Matulonis on the Current Treatment Landscape of Recurrent Ovarian Cancers

June 20th 2022

Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. George on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 19th 2022

Mridula George, MD, discusses the clinical implications of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

June 19th 2022

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Dr. Yee on Treating Patients with Relapsed Disease in Multiple Myeloma

June 19th 2022

Andrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.

Dr. George on the Background of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

June 16th 2022

Mridula George, MD, discusses the background of the phase 3 DESTINY-Breast04 trial in breast cancer.

Dr. Llanos on Recognizing Social Determinants of Disparities in Cancer Care

June 16th 2022

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.